Following the patent expiry, Accord UK is pleased to announce the launch of Dutasteride 0.5mg Soft Capsules. This product launch further strengthens the expanding Accord UK portfolio.
Dutasteride 0.5mg Soft Capsules are indicated in the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) and reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.
All Accord products are available through major wholesalers or directly from our UK based sales team on free phone: 0800 731 0370 or fax: 0800 731 0380 (calls may be recorded for training or quality purposes).
Pete Kelly, Managing Director of Accord UK comments: “A strong passion for R&D helps us to evolve and innovate to meet the needs of our customers in a dynamic market place. We remain committed to bringing cost competitive products to market at the earliest opportunity, with the launch of Dutasteride 0.5mg Soft Capsules being our latest day one patent expiry launch.”
“As a partner of choice for our customers, we not only focus on innovation, but we also invest in services such as the Accord Scheme (www.accordscheme.com) which offers pharmacists transparent, simple, competitive net pricing and ease-of-use.”
Accord’s growing portfolio currently features over 850 product lines across a wide variety of therapy areas.
|Dutasteride Soft Capsules||0.5mg||121-8171||30||£7.30|